ClinicalThought Commentary

Share

Program Content

Activities

  • AEs With CAR T-Cell and Bispecific Antibody Tx in MM
    Thinking Through Key Considerations for Emergency Medical Professionals on the Management of Patients With Myeloma Receiving CAR T-Cell Therapy or Bispecific Antibodies
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 22, 2024

    Expires: May 21, 2025

Faculty

cover img faculity

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

ProCE Banner

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC